http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-39276-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97a285d8ecd0184a7e5d89a1e4e07997 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-68 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-68 |
filingDate | 1974-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 1978-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | IE-39276-B1 |
titleOfInvention | Hypocholesterolemic compositions |
abstract | Calcium alpha -p-chlorophenoxyisobutyrate, particularly as its novel monohydrate, when combined with about one to two parts by weight of calcium carbonate in oral dosage form for use in mammals, and especially man, provides a safe and effective composition for reducing elevated blood levels of cholesterol, triglycerides and/or low density lipoproteins and/or increasing fibrinolytic activity and/or decreasing platelet aggregation. A preferred embodiment is a capsule containing 500 mgm. calcium carbonate and 250 or 500 mgm. crystalline calcium alpha -p-chlorophenoxyisobutyrate monohydrate having the empirical formula C10H10ClO3Ca1/2.H2O.n[US3952096A] |
priorityDate | 1973-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.